Johnson & Johnson

NYSE:JNJ

Drug Manufacturers - General

Healthcare
$272.70 -1.96%

-$4.59 today

Market cap
$656.47B
Beta
0.26
P/E (TTM)
26.7
EPS (TTM)
$8.60
Dividend yield
2.28%
52W Low $149.04High $251.71

Volume 7.93M

Average 7.71M

JNJ Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Johnson & JohnsonNYSE: JNJ

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $4.65B rose 26.7% year over year, ahead of the +2.4% change in trailing-twelve-month research & development. Sequentially, it rose 27.3% from the prior quarter. Over 3 fiscal years it compounded at +1.2% a year.

Context

  • Research & development amounted to 15.6% of revenue in FY2025, down 3.8 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +26.7% holds above the trailing-twelve-month pace of +2.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$4.65B+27.3% QoQ
Last fiscal yearDec 2025
$14.67B-14.9% YoY
LTMSep 2026
$16.08B+2.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.7%——
1 year-14.9%——
3-year CAGR+1.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
14.67B USD
Year-over-year change
-14.9%
4-year CAGR
+0.7%

Research & Development vs competitors

How JNJ compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.4% is the 9th highest of 11, against a peer median of +6.2%.
  • Research & development amounts to 16.2% of revenue for JNJ, versus a peer median of 20.2%.
JNJ Competitors
Research & Development for JNJ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$28.35B USD+65.7%-2.6%42.7%
JNJJohnson & JohnsonLTM Sep 2026$16.08B USD+2.4%+1.2%16.2%
AZNAstraZeneca PLCLTM Sep 2026$15.01B USD-0.3%+13.4%24.1%
NVSNovartis AGLTM Jun 2026$11.28B USD+9.2%+5.4%20.3%
PFEPfizer Inc.LTM Jun 2026$11.05B USD+7.0%-3.0%17.3%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$10.72B USD+3.1%+1.5%21.8%
ABBVAbbVie Inc.LTM Sep 2026$9.96B USD-25.0%+11.8%15.1%
GSKGSK plcLTM Jun 2026£9.2B GBP+31.8%+11.1%27.7%
SNYSanofiLTM Jun 2026€8.11B EUR+5.4%+6.5%16.6%
AMGNAmgen Inc.LTM Jun 2026$7.64B USD+19.3%+16.3%20.0%
GILDGilead Sciences, Inc.LTM Jun 2026$6.07B USD+2.7%+5.2%19.9%
Peer median (excluding JNJ) —+6.2%+5.9%20.2%

Competitors are the stored peer set for JNJ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.74B79.99B85.16B88.82B94.19B
Cost of Revenue23.4B24.6B26.55B27.47B30.26B
Gross Profit55.34B55.39B58.61B61.35B63.94B
Gross Margin70.3%69.3%68.8%69.1%67.9%
Research & Development14.28B14.14B15.09B17.23B14.67B
Selling, General & Admin20.12B20.25B20.11B21.97B23.68B
Operating Expenses34.4B34.38B35.2B39.2B38.34B
Depreciation & Amortization7.39B6.97B7.49B7.34B7.5B
EBITDA26.75B26.61B23.32B24.78B41.06B
EBITDA Margin34.0%33.3%27.4%27.9%43.6%
Operating Income20.94B21.01B23.41B22.15B25.6B
Operating Margin26.6%26.3%27.5%24.9%27.2%
Interest Income53M490M1.26B1.33B1.06B
Interest Expense183M276M772M755M971M
Other Income / Expenses(1.77B)(1.65B)(8.35B)(5.46B)6.99B
Income Before Tax19.18B19.36B15.06B16.69B32.58B
Pre-Tax Margin24.4%24.2%17.7%18.8%34.6%
Income Tax Expense1.38B2.99B1.74B2.62B5.78B
Net Income20.88B17.94B35.15B14.07B26.8B
Net Margin26.5%22.4%41.3%15.8%28.5%
EPS (Basic)7.936.8313.885.8411.03
EPS (Diluted)7.816.7313.725.7911.03
Weighted Avg Shares2.63B2.61B2.53B2.41B2.43B
Weighted Avg Shares (Diluted)2.67B2.66B2.56B2.43B2.43B

Johnson & Johnson

NYSE:JNJ

Intrinsic Alpha fair value

Locked

Current Price

$272.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.